Diabetes Research and Clinical Practice
Volume 72, Issue 1 , Pages 48-52 , April 2006

Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control

  • S.H. Md Isa

      Affiliations

    • Department of Medicine, National University of Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia
    • Corresponding Author InformationCorresponding author. Tel.: +60 3 9173 3333x3833/2787; fax: +60 3 9173 7829.
    • ,
  • I. Najihah

      Affiliations

    • Department of Medicine, National University of Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia
    • ,
  • W.M. Wan Nazaimoon

      Affiliations

    • Diabetes and Metabolic Disorders Unit, Institute for Medical Research, Jalan Pahang, Kuala Lumpur 50588, Malaysia
    • ,
  • N.A. Kamarudin

      Affiliations

    • Department of Medicine, National University of Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia
    • ,
  • N.A. Umar

      Affiliations

    • Department of Chemical Pathology, National University of Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia
    • ,
  • N.H. Mat

      Affiliations

    • Department of Medicine, National University of Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia
    • ,
  • B.A.K. Khalid

      Affiliations

    • Department of Medicine, National University of Malaysia, Jalan Yaacob Latif, Cheras, Kuala Lumpur 56000, Malaysia

Received 2 July 2004 ,Revised 28 April 2005 ,Accepted 7 September 2005.

References 

  1. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  2. Ohkubo Y, Kishikawa H, Araki E. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diab. Res. Clin. Pract. 1995;28:103–117
  3. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679–684
  4. Marx N, Schonbeck U, Lazar MA, et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 1998;83:1097–1103
  5. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6 and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334
  6. Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Nijpels G, Dekker JM, et al. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study. Diabetes. 2000;49:485–491
  7. Venugopal SM, Devaraj S, Ishwarlal J. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proartherogenic role. Curr. Opin. Nephrol. Hypertens. 2005;14:33–37
  8. Schmidt AM, Yan DS, Wautier JL, Stern D. Activation of receptor for advanced glycation end-products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and artherosclerosis. Circ. Res. 1999;84:489–497
  9. Wan Nazaimoon WM, Khalid BAK. An enzyme immunoiassay for advanced glycosylation end-products in serum. Mal. J. Pathol. 1998;20:83–89
  10. Nakayama H, Taneda S, Mitsuhashi T, Kuwajima S, Aoki S, Kuroda Y, et al. Charaterisation of antibodies to advanced glycosylation end-products on protein. J. Immunol. Meth. 1991;140:119–125
  11. King DE, Mainous AG, Buchanan TA, Pearson WS, William S. C-reactive protein and glycaemic control in adults with diabetes. Diab. Care. 2004;27:637–638
  12. Chu J, Abbasi F, Lamendola C, Mclaughlin T, Tsao P, Reaven G. Improvements in vascular and inflammatory markers in rosiglitazone-treated insulin-resistant subjects are independent of changes in insulin sensitivity or glycaemic control. Diabetes. 2003;52S:A76
  13. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease and prevention. Circulation. 2003;107:363–369
  14. Vlassara H, Palace MR. Diabetes and advanced glycation end-products. J. Intern. Med. 2002;251:87–101

☆ This work received funding from an educational grant from the National University of Malaysia, GlaxoSmithKline and Aventis Pharma.

PII: S0168-8227(05)00376-1

doi: 10.1016/j.diabres.2005.09.011

Diabetes Research and Clinical Practice
Volume 72, Issue 1 , Pages 48-52 , April 2006

Article Tools